Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.
Scilex Holding Company (NASDAQ: SCLX) announced it will present a post-hoc analysis of their C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) from May 15-17, 2025 in Orlando, FL. The presentation will focus on interpreting the clinical meaningfulness of safety and efficacy data for SP-102 (SEMDEXA™) in treating lumbosacral radicular pain (LRP).
The poster presentation will be displayed throughout the meeting and will be accessible via the conference app. Additionally, it will be published in the Pain Physician journal. The research was conducted by a team of authors including Miller AM, Knezevic NN, Nalamachu S, and others.
Scilex Holding Company (NASDAQ: SCLX) ha annunciato che presenterà un'analisi post-hoc del loro studio C.L.E.A.R. (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) al 27° Congresso Annuale della American Society of Interventional Pain Physicians (ASIPP), che si terrà dal 15 al 17 maggio 2025 a Orlando, FL. La presentazione si concentrerà sull'interpretazione della rilevanza clinica dei dati di sicurezza ed efficacia di SP-102 (SEMDEXA™) nel trattamento del dolore radicolare lombo-sacrale (LRP).
Il poster sarà esposto per tutta la durata del congresso e sarà accessibile tramite l'app della conferenza. Inoltre, sarà pubblicato sulla rivista Pain Physician. La ricerca è stata condotta da un team di autori tra cui Miller AM, Knezevic NN, Nalamachu S e altri.
Scilex Holding Company (NASDAQ: SCLX) anunció que presentará un análisis post-hoc de su ensayo C.L.E.A.R. (Analgésicos epidurales lumbares con corticosteroides en radiculopatía) en la 27ª Reunión Anual de la Sociedad Americana de Médicos Intervencionistas del Dolor (ASIPP) del 15 al 17 de mayo de 2025 en Orlando, FL. La presentación se centrará en interpretar la relevancia clínica de los datos de seguridad y eficacia de SP-102 (SEMDEXA™) en el tratamiento del dolor radicular lumbosacro (LRP).
La presentación en formato póster estará disponible durante toda la reunión y se podrá acceder a ella a través de la aplicación de la conferencia. Además, será publicada en la revista Pain Physician. La investigación fue realizada por un equipo de autores que incluye a Miller AM, Knezevic NN, Nalamachu S y otros.
Scilex Holding Company (NASDAQ: SCLX)는 2025년 5월 15일부터 17일까지 플로리다 올랜도에서 열리는 제27회 미국 중재적 통증의학회(ASIPP) 연례회의에서 C.L.E.A.R. 임상시험(척추 신경근병증에 대한 코르티코스테로이드 요추 경막외 진통제)의 사후 분석 결과를 발표할 예정입니다. 발표는 요추천골 신경근통(LRP) 치료에 있어 SP-102 (SEMDEXA™)의 안전성과 효능 데이터의 임상적 의미 해석에 중점을 둘 것입니다.
포스터 발표는 회의 기간 내내 전시되며, 회의 앱을 통해서도 접근할 수 있습니다. 또한, 해당 연구는 Pain Physician 저널에 게재될 예정입니다. 연구진에는 Miller AM, Knezevic NN, Nalamachu S 등 여러 저자가 참여했습니다.
Scilex Holding Company (NASDAQ : SCLX) a annoncé qu'elle présentera une analyse post-hoc de leur essai C.L.E.A.R. (Analgésie épidurale lombaire par corticostéroïdes dans la radiculopathie) lors de la 27e réunion annuelle de l'American Society of Interventional Pain Physicians (ASIPP), qui se tiendra du 15 au 17 mai 2025 à Orlando, FL. La présentation portera sur l'interprétation de la signification clinique des données de sécurité et d'efficacité de SP-102 (SEMDEXA™) dans le traitement de la douleur radiculaire lombo-sacrée (LRP).
Le poster sera exposé tout au long de la réunion et accessible via l'application de la conférence. De plus, il sera publié dans la revue Pain Physician. La recherche a été menée par une équipe d'auteurs comprenant Miller AM, Knezevic NN, Nalamachu S et d'autres.
Scilex Holding Company (NASDAQ: SCLX) gab bekannt, dass es eine Post-hoc-Analyse ihrer C.L.E.A.R.-Studie (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) auf dem 27. Jahrestreffen der American Society of Interventional Pain Physicians (ASIPP) vom 15. bis 17. Mai 2025 in Orlando, FL, vorstellen wird. Die Präsentation wird sich auf die Interpretation der klinischen Relevanz der Sicherheits- und Wirksamkeitsdaten von SP-102 (SEMDEXA™) bei der Behandlung von lumbosakralem radikulärem Schmerz (LRP) konzentrieren.
Das Poster wird während der gesamten Tagung ausgestellt und ist über die Konferenz-App zugänglich. Zusätzlich wird es im Pain Physician Journal veröffentlicht. Die Forschung wurde von einem Autorenteam unter anderem mit Miller AM, Knezevic NN und Nalamachu S durchgeführt.
- None.
- None.
PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced an upcoming presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.
| Poster Content: | Interpreting Clinical Meaningfulness of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP): A Post-hoc Analysis |
| of the CLEAR-1 Trial and A Systematic Review of Literature | |
| Authors: | Miller AM, Knezevic NN, Nalamachu S, Meske D, Ambrose C, Vought K, Chan EK, and Lissin D. |
The poster will be on display throughout the meeting from Thursday, May 15 through Saturday, May 17, 2025, allowing all attendees to view it. It will also be available via the conference app and will be published in the Pain Physician journal.
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com
For more information on ZTlido®, including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex Holding Company is headquartered in Palo Alto, California.
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding upcoming presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP).
Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex’s ability to remain in compliance with the Nasdaq continued listing requirements and to maintain the listing of the Company’s securities thereon; Scilex’s ability to develop and commercialize treatments for obesity, neurodegenerative, and cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2025 Scilex Holding Company All Rights Reserved.
FAQ
What will SCLX present at the ASIPP 2025 Annual Meeting?
When and where is Scilex presenting their SP-102 trial analysis?
How will the SCLX poster presentation be made available?
What is SP-102 being developed to treat?
